Oppenheimer lowered the firm’s price target on Bioceres to $16 from $17 and keeps an Outperform rating on the shares. The firm remains constructive on Bioceres as it exits an uneven recovery year and enters FY25 with a keen focus on working capital and revenue efficiency. Oppenheimer is lowering its FY25 topline outlook for muted growth amid the challenging ag macro backdrop, while strengthening its margin assumptions as the company transitions its go-to-market model for HB4 for capital efficiency.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue